To describe the international landscape of clinical trials in carbon-ion radiotherapy (CIRT), the authors reviewed the current status of 63 ongoing clinical trials (median, 47 participants) involving CIRT identified from the US clinicaltrials.gov trial registry and the World Health Organization International Clinical Trials Platform Registry. The objectives were to evaluate the potential for these trials to define the role of this modality in the treatment of specific cancer types and identify the major challenges and opportunities to advance this technology. A significant body of literature suggested the potential for advantageous dose distributions and, in preclinical biologic studies, the enhanced effectiveness for CIRT compared with photons and protons. In addition, clinical evidence from phase I/II trials, although limited, indicated the potential for CIRT to improve cancer outcomes. However, current high-level phase III randomized clinical trial evidence does not exist. Although there has been an increase in the number of trials investigating CIRT since 2010, and the number of countries and sites offering CIRT is slowly growing, this progress has excluded other countries. Several recommendations are proposed to study this modality to accelerate progress in the field, including: 1) increasing the number of multinational randomized clinical trials, 2) leveraging the existing CIRT facilities to launch larger multinational trials directed at common cancers combined with high-level quality assurance; and 3) developing more compact and less expensive next-generation treatment systems integrated with radiobiologic research and preclinical testing. Cancer 2018;124:4467-4476.
INTRODUCTION
Nearly one-half of patients with newly diagnosed cancer will undergo radiotherapy (RT), a form of treatment that has been available for more than 100 years. 1 Most of these patients receive a form of external-beam RT (EBRT) using photons (aka x-rays). Over the past 10 years, there has been increased interest in the development of more sophisticated forms of EBRT, the most popular of which is proton-beam RT (PBRT).
A comprehensive review of the evidence for PBRT was recently published. 2 The authors of that review concluded that, although the proton therapy clinical trial portfolio was rapidly expanding, and most patients had been accrued to observational studies, they also acknowledged the need to evaluate those ongoing trials in terms of comparative effectiveness with conventional RT modalities. Most important, despite the comprehensiveness of their review, noticeably absent was any high-level evidence that proton-based treatment resulted in improved clinically significant results for any specific cancer type, site, or age group compared with other forms of RT. Currently, there are ongoing randomized phase II and III studies comparing protons versus photons for low-grade brain tumors and cancers of the oropharynx, esophagus, lung, breast, prostate, and liver.
Growing numbers of facilities around the world are treating patients with cancer who have tumors that are considered resistant to photons using a highly targeted form of RT with potential physical and biologic advantages over PBRT: namely, carbon-ion RT (CIRT). 3, 4 The objectives of the current review were to describe the current status of this potentially more advanced form of RT, to list the major logistic and technical challenges hampering the widespread adoption of this technology, to summarize the clinical work completed to date, and to provide recommendations for how these challenges might best be overcome.
Cancer December 1, 2018 CARBON-ION RADIOTHERAPY On the basis of the theoretical and early experimental biologic advantages of CIRT compared with PBRT, several research centers around the world have chosen to pursue this treatment modality since the late 1970s, 3, [5] [6] [7] [8] although it incurs much higher initial investment costs. 9, 10 Currently, approximately 20,000 patients worldwide have received CIRT according to the Particle Therapy Cooperative Group database (available at: https://ptcog. ch/index.php/clinical-protocols. Accessed July 16, 2017) . The technology for RT with ions heavier than protons was originally developed in the United States at the Lawrence Berkeley National Laboratory (LBNL). 11 The first phase I/II trials with helium and neon ions were conducted in collaboration with the LBNL at the University of California San Francisco more than 40 years ago. 5, [12] [13] [14] [15] Unfortunately, funded follow-up of phase I/II clinical trial results from the University of California San Francisco/LBNL cohort ended shortly after enrollment because of a budget-forced closure of the facility.
Starting in 1994, CIRT technology was further developed for numerous tumor sites at the Heavy Ion Medical Accelerator (HIMAC) facility operated by the National Institute of Radiological Sciences in Chiba, Japan. Although the first carbon-ion cancer treatments were initiated in Berkeley, California, the first phase I/II trials with carbon ions were completed at the HIMAC, 16 and the Japanese program has accrued the most extensive experience with CIRT worldwide. 3 During the ramp-up phase of the HIMAC CIRT program between June 1994 and August 2003, more than 1600 patients with tumors in various sites were enrolled in phase I/II dose-escalation studies and clinical phase II studies. These trials and the clinical experience gathered with them were summarized in a previous review. 16 A second clinical facility for CIRT, the German Heidelberg Ion Therapy (HIT) Center, started treating patients in November 2009. This center followed the pioneering work at the experimental CIRT facility of the Institute for Heavy Ion Research (Gesellschaft fur Schwerionen Forschung) in Darmstadt, Germany, that advanced the use of 3-dimensional, scanned-beam delivery between 1998 and 2009 and was the first facility in the world to build a CIRT gantry. Additional clinical CIRT facilities have opened in Japan (5 facilities total), Germany (2 facilities total), Italy (1 facility), China (2 facilities), and Austria (1 facility as of 2017). Currently, there are 11 CIRT facilities worldwide. Figure 1 provides schematic examples allowing the readers to get an impression of the size of the CIRT facility, located in Gunma, Japan (available at:
http://heavy-ion.showa.gunma-u.ac.jp/en/page.php?id=5. Accessed September 12, 2018) . Figure 1A displays the perimeter of this facility, which measures 45 × 65 meters (about one-half the size of a professional soccer field at 45 × 120 meters). A linear accelerator provides acceleration to the carbon ions before they are injected into the synchrotron and accelerated up to 70% of the speed of light. Keeping the heavy ions on a circular track requires very large dipole magnets, making conventional (nonsuperconducting) synchrotrons for CIRT very large (approximately 60 meters in circumference). The patients receive irradiation with the accelerated carbon ions in the treatment room. Figure 1B shows an individual standing next to the pioneering carbon ion gantry constructed at the HIT Center in Heidelberg, Germany, again displaying the relative stature of this very large steel construction (25 meters long, 13 meters in diameter, and weighing 670 tons). The Japanese have developed a CIRT gantry that has one-half the weight of the HIT gantry and produces a 20 × 20 cm field.
Because of the physical dose distributions of the carbon-ion Bragg ionization curve (ie, greater energy disposition within the Bragg peak and enhanced biologic properties of the stopping ions with high linear energy transfer [high-LET]), carbon-ion beams potentially can target tumor cells with greater precision while minimizing damage to surrounding tissues. Carbon ions can be used to reduce doses to surrounding normal tissue volumes because of their sharper lateral penumbra. With the use of heavier ions like carbon, high-LET radiation effects translate into an increased relative biologic effectiveness (RBE) value by at least a factor of 2-fold or 3-fold relative to photons, depending on the treatment volume. 18 Protons have RBE values that, for the most part, are only slightly higher than unity relative to photons. 19 Although RBE is an important factor when selecting a radiation dose, there are additional advantages associated with high-LET radiation that can contribute to survival benefits. 8, 20 For example, there are animal and human data suggesting that there is an increased immunestimulatory effect with CIRT compared with photons. 21 The current clinical evidence from phase I/II trials suggests a role for CIRT in various relatively rare tumors. For example, Schulz-Ertner reviewed their experience using CIRT in 2009 to treat several tumor sites, including sarcomas of the base of skull (chordomas and chondrosarcomas). 4 The patient cohorts were small, but the evidence suggested that there is likely to be an advantage for CIRT over PBRT, particularly for avoiding late normal tissue effects. However, a recent publication suggests that equivalent control rates and outcomes were achieved by 101 patients with skull-based chondrosarcomas who received either protons or carbon ions using intensity-modulated, active raster scanning. 22 Furthermore, the published evidence for long-term late effects from these and other therapies is sparse. There is the potential for considerable variability in the RBE of CIRT used clinically and, to a lesser degree, of protons, depending on the biologic models, treatment planning protocols, and treatment volumes currently in use. 23, 24 NORTH AMERICAN INTEREST IN CIRT The physical, biologic, and cost-effective advantages have led us to pursue this field of research through the North American Particle Alliance (NAPTA), which was formed in 2013 to advance the development of therapy with carbon and other ions in the United States and worldwide. 24, 25 Our work was predicated on the assumption that there was a sufficient body of evidence to justify the re-establishment of a CIRT center in the United States. However, it has been estimated that the cost of a US facility with existing CIRT technology is approximately $200 to $300 million US dollars. A consensus was reached among NAPTA investigators that to justify the cost associated with current CIRT technology, definitive studies (ie, high-level, phase III, randomized clinical trials) would be needed to prove the efficacy of CIRT over protons or other forms of advanced but less expensive x-raybased therapy, such as intensity-modulated radiation (IMRT) or stereotactic body radiation therapy (SBRT).
The objectives of the current review were to catalog the status of recently completed and ongoing CIRT clinical trials and to review the progress made to date in obtaining clinical evidence. We also set out to determine whether it is likely that the current clinical trials will provide compelling evidence to justify the routine use of CIRT for the treatment of patients with cancer despite the higher cost associated with these treatments. More specifically, we sought: 1) to summarize the current status of recent and ongoing clinical trials; 2) to assess whether these trials will provide the necessary high-level evidence to establish superiority of the efficacy of CIRT over current forms of radiotherapy in different tumor sites; 3) to summarize technical, radiobiologic, and logistic challenges to further advance CIRT in the United States; 4) to propose improvements in trial design (if justified); 5) to propose strategies for ensuring that the suggested trials are initiated as fiscally responsible as possible; and 6) to the degree possible, to lay the groundwork for ensuring that this technology becomes widely available when it is justified by the evidence.
STATUS OF CIRT TRIALS
In total, 63 clinical trials involving CIRT met the inclusion criteria outlined in the Supporting Information. The vast majority of the 63 trials were nonrandomized (84%) compared with 10 trials that were randomized (16%). The median intended enrollment was 47 participants (from a minimum of 6 to a maximum of 689 participants). The trials with nonrandom allocation (n = 53), as expected, had a lower median enrollment goal of 40 participants (from a minimum of 6 to a maximum of 689 participants) compared with the larger median enrollment of 152 participants (from a minimum of 50 to a maximum of 436 participants) for those with random allocation. Nearly all of the clinical trials recruited adults only (54 trials; 86%) or recruited adults and pediatric patients (8 trials; 13%), and 1 trial (2%) exclusively studied children only. Of the 63 clinical trials, most were conducted in Japan (38 trials; 60%), followed by Germany (16 trials; 25%), China (7 trials. 11%), and Italy (1 trial; 2%). One trial (2%) of radioresistant head and neck (H&N) tumors was developed in France and will be conducted at the HIT Center in Germany. Two nonrandomized trials and a single randomized trial were considered completed, whereas nearly one-half of the trials (49%) were still recruiting participants. Nine trials (14%) were not yet recruiting, 7 trials (11%) were no longer recruiting, 9 trials (14%) had unknown recruitment status, and 3 trials (5%) were terminated before completion.
CLINICAL ENDPOINTS AND STUDY PHASE OF CIRT TRIALS
The primary endpoint for the majority of clinical trials (32 of 63 trials; 51%) was adverse events (13 trials) or toxicity and/or dose response (19 trials), followed by local control in 15 trials (24%), progression-free survival in 9 trials (14%), and overall survival (OS) in 7 trials (11%). Of the 10 randomized trials, 1 phase II trial (10%) included OS as the primary endpoint, 2 (20%) used progressionfree survival as an endpoint, 4 (40%) used an adverse event or toxicity and/or a dose-response endpoint, and 3 (30%) focused on local control. It is noteworthy that, of the 10 randomized clinical trials, 30% were classified as phase III, and those phase III trials represented 5% (n = 3 of 63 trials) of all trials involving CIRT. China, and Germany. The additional 6 facilities opened after 2010, and the most recent addition was in Austria (2017). The number of phase II trials increased in 2010, but not the number of phase III trials. Indeed, very few phase III trials were initiated in the last 5 years. Figure 3 displays the study disease sites of CIRT trials according to study phase. Most sites studied were phase I/II trials or combined phase I/II trials. Phase III trials were limited to sites in the base of skull (n = 2) and H&N (n = 1). Most trials with random allocation were activated in Germany; ie, 7 trials (70%) in Germany, 2 trials (20%) in Japan, and 1 trial (10%) was conceived in France (the latter will be conducted at the HIT Center in Germany). All of these trials randomized adults, comparing carbon therapy with either PBRT (7 trials; 70%), photon therapy (2 trials; 20%), or neoadjuvant therapy (1 trial; 10%) by using α-galactosylcerimide-pulsed antigen followed by CIRT.
Various disease sites are or were under investigation, including (in order of frequency): 14 H&N trials (22%), 11 prostate trials (18%), and 6 liver trials (10%). Among the 10 randomized trials, 3 were central nervous system (CNS) trials (30%), 2 were H&N trials (20%), and 2 were base-of-skull trials (20%), altogether accounting for 70% of the ongoing randomized trials (with 1 of the most common cancers, prostate cancer, tested only in a single randomized trial; 10%).
CHALLENGES AND FUTURE DIRECTIONS
This review assesses the CIRT trial landscape evaluating where we stand in terms of clinical evidence and how rapidly progress is advancing. Mark Twain has been credited with saying, "the best predictor of future behavior is past behavior." Although this aphorism is directed at predicting human behavior, we believe it is also very likely to be predictive of the direction of scientific and clinical research in general and specifically of progress in CIRT. This saying may also provide insights into which clinical sites might be selected for studies in the context of moving forward with phase III trials (see Discussion, below). Although there are modest numbers of trials involving CIRT that have been completed in recent times or are currently being conducted, as described above, a minority are randomized, a smaller minority are phase III trials, and even fewer involve an OS primary endpoint.
Despite recent international consensus for a model-based approach to particle-beam therapy that includes patient selection, nonrandomized trials based on highly selected patients are inadequate for providing high-level evidence for the efficacy of CIRT required to justify the construction of new facilities. 26 Only 5% of all of the CIRT trials reviewed here are phase III comparative randomized trials, and none of these involve OS as an endpoint. Only 1 randomized trial involves prostate cancer, which is the most common cancer disease in the Western world, and very few randomized trials have been initiated in the past 3 years. Thus, the prospects are slim for the completion of a registration type trial that could establish definitively the value of CIRT in the near future. If substantial progress in the distant future is to be made in clinical CIRT research, then it appears most likely that it would involve Germany and/or Japan: the 2 countries with the largest current activity in CIRT, prostate trials, and basic research. [27] [28] [29] [30] [31] [32] However, the current trials being conducted have provided inspiration, direction, and potentially useful resources for the future of CIRT.
Furthermore, even when the same CIRT dose is prescribed in a trial from Japan or a European site, the tumors (and normal tissues) may be receiving different carbon doses of radiation because of facility-dependent protocols and assumptions in the biologic models used for treatment planning of effective doses. Thus, going forward, we would propose reaching a consensus when possible but, at a minimum, capturing detailed dosimetric and clinical information so that clinical outcomes can be used to adjudicate these differences of opinion. 16, 33, 34 We previously coined the mnemonic "RESIDUE" to call attention to 7 major challenges that need to be solved to advance this field and allow CIRT to be widely available. 25 These 7 major "RESIDUE" challenges are as follows:
1. Radiobiologic knowledge to address uncertainty in optimal fraction sizes and doses and relative biologic effectiveness for each tumor site (biologic); 2. Exchange of technology, funding, and infrastructure between academic centers, health care payers, industry, and funding agencies (operational); 3. Size/weight of accelerators and gantries (engineering/ physics and cost);
4. Integration of technology to advance key areas from beam acceleration and delivery through treatment planning and image guidance (engineering/physics to create equipoise with x-ray-based treatment); 5. Define the patient population to be studied-that is, identify and select patients who will benefit the most from CIRT (clinical); 6. Uncertainties of effective dose and range at the end of the Bragg peak (physics and accuracy); and 7. Evidence of clinical effectiveness and cost effectiveness (societal).
The first issue will give direction and create new hypotheses but ultimately will require validation in humans, because animal models may not be precise enough to accurately predict the benefits of this technology in humans, although even this issue is highly debated. 35, 36 It may be useful to leverage the available human cancer transcriptome-based data to move this field forward. 37 The open-access Human Pathology Atlas database (available at: www.proteinatlas.org/pathology. Accessed July 16, 2017) allows for genome-wide exploration of the impact of individual proteins on clinical outcomes in major human cancers. If existing patient biopsy materials become available from patients who receive CIRT, then specific tumor protein profiles could be correlated with clinical outcomes and could be used prognostically to identify patients for whom CIRT is appropriate.
Among the RESIDUE challenges, issues 2 and 3 (see above) represent true challenges to building new CIRT facilities in the United States but also are opportunities that could lead to improved cost effectiveness. Issues 4 and 6 (see above) can be readily accomplished through ongoing research in existing facilities (such as work currently being performed by NAPTA members) 25 and future research-oriented facilities. This leaves primarily issues 5 and 7 to be addressed. To this end, large, robust trials with clinically meaningful endpoints (foremost, OS or the time to metastatic disease [eg, prostate cancer]) should be developed (issue 5), which eventually allow us to address issue 7 and justify further investment into new technology development. 38 These trials must include not only rare and challenging diseases, but also common diseases (as discussed in more detail below).
Cancer Sites Suitable for Clinical Trials
Japan and Germany have demonstrated that there are several selected sites for which CIRT potentially may be beneficial. To gain widespread acceptance, it is important not to limit the utility of CIRT to rare radiation-resistant tumors. The tumor site most frequently treated in Japan with CIRT has been prostate cancer. To establish CIRT as a standard treatment option, common cancers should be studied in prospective trials in which patients receive definitive treatment with a very limited number of fractions. This argument is based on the observation that SBRT appears to be at least as effective as doseescalated conventionally fractionated photons for several common solid tumors (eg, lung and prostate cancers) and on the finding that physical dose targeting of the tumor by CIRT spares normal tissues and reduces the need to fractionate the dose. 39, 40 There also may be additional biologic mechanisms underlying improved treatment outcomes of CIRT when it is administered in a few fractions.
The use of different treatment planning systems, techniques, and assumptions concerning RBE and LET models potentially could complicate the interpretation of outcomes for patients who receive treatment in Japan, Europe, and elsewhere. 33 For example, Japan had relied on their prior extensive neutron experience (involving similar high-LET effects) to guide their initial clinical approach to CIRT carbon ions for treatment planning to have similar effects. The Japanese program has now matured to a modified microdosimetric kinetic model-based approach. 18, 41, 42 For several European centers, conversely, a local effects model is used that calculates the probability of a lethal event based on nanometer features of track structure. We believe that it is critical that future trials of a given cancer site not be confined to 1 center with CIRT capability. We must first standardize certain elements of treatment and ensure a very high level of quality assurance. To this end, we have begun a program to use anthropomorphic human as well as virtual phantoms to investigate issues like range uncertainty and to incorporate image-guidance techniques into these trials. [43] [44] [45] Figure 3 indicates that, based on available empirical clinical data, cancers of the H&N, prostate, liver, pancreas, as well as bone and soft tissues appear to have been identified by investigators as the most suitable for enrollment onto phase I or phase I/II trials involving CIRT. Thus, we would favor focusing on patients with locally advanced disease (eg, T3-T4) in these sites. Two phase III trials involving pancreatic cancer have recently been launched (described below 8 ), and trials involving sarcomas and liver primaries are in the planning stages. Another phase III trial launched in France (and to be conducted at the HIT Center in Germany) plans to study radio-resistant H&N tumors. This is an excellent start to multinational trials. However, all of these phase III trials are being conducted at single centers, and we believe multicenter, international trials are essential for optimal recruitment and generalizability. A detailed discussion of trials required for each of these cancer sites is beyond the scope of this review; however, in general, multiple stratification variables may need to be incorporated into the design to ensure balanced recruitment, particularly for sites with large patient heterogeneity (eg, H&N cancers).
One site under discussion by our own group (NAPTA), in collaboration with the leadership of several centers with CIRT capability, involves the design of a large phase II/III clinical trial for men with unfavorable intermediate-risk and high-risk prostate cancer. The rationale for choosing this cancer site is as follows: 1) Prostate cancer is one of the most common cancers treated definitively with radiation in the world and is the most common cancer treated with CIRT. 3, 30 2) Increasingly, SBRT is being used to treat both intermediate-grade and high-grade prostate cancer, either as a monotherapy in 4 or 5 fractions or as a boost with 2 fractions after pelvic radiotherapy; and, recently, several investigators have begun studying the feasibility of treating prostate cancer with a single fraction 40 (clinicaltrials. gov identifier NCT03294889). 3) There are theoretical reasons to believe that CIRT, because of the tighter penumbra, should allow increased sparing of neurovascular structures and the penile bulb, resulting in improved erectile function and favorably impacting quality of life. [46] [47] [48] 4) The higher RBE and sharper lateral fields of CIRT, permitting biologic and physical dose escalation, should improve local control more than might be expected with photon-based or proton-based SBRT. 40 5) Hypoxia and other mechanisms of radiation resistance thought to confer resistance to photon-based EBRT may be overcome
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27,49-51 And 6) intermediate endpoints, such as prostate-specific antigen nadir and/or time to metastatic disease, could be used to support the viability of CIRT. 38, 40, 52, 53 Patients with prostate cancer (including those from the United States) initially would receive treatment with 4 or 5 fractions of SBRT using photons (x-rays) versus protons versus CIRT (with photons considered the standard to which the others are compared), as noted above. Subsequently, we would evaluate the feasibility of managing this disease with a single fraction. This would allow us to answer questions related to dose distributions advantages (charged particles vs photons) and RBE (photons and protons vs carbon). One concern that might be voiced by some authorities is whether radiation limited to the prostate (excluding the pelvic lymph nodes) would be appropriate for patients with intermediate-risk or highrisk disease. Fortunately, it is anticipated that the results of Radiation Therapy Oncology Group Study RTOG 0924 (a phase III trial testing the value of whole pelvic radiotherapy in patients with unfavorable intermediate-risk and high-risk disease) should be available in the next few years (anticipated completed accrual, n = 2580 in May 2019; Mack Roach III, MD, principal investigator [personal communication]). 54 This should allow investigators to complete the due diligence required to address the technical challenges associated with range uncertainty and image guidance. It also should guarantee the required accuracy for designing and launching the appropriate clinical trial.
25,55

Limitations of Review
There are several limitations to this review. Although we provide an up-to-date summary, a few trials may have been missed because of oversight or because they were not included for reasons of an absence of sufficient available detail. Additional trials are being planned in Japan and may open soon. 56 For example, we have become aware of 2 trials that are being planned in the United States, to be conducted in foreign centers, but were not yet registered in clinicaltrials.gov or with the World Health Organization at the time this review was written. This includes a trial designed by investigators from the University of Texas Southwestern Medical Center (Dallas, Texas), known as CIPHER (Carbon Ion Versus Photon Therapy for Pancreatic Cancer), and another phase III trial funded by the US National Cancer Institute to study CIRT versus IMRT for pancreatic cancer in patients at the Shanghai Proton and Heavy Ion Center (Shanghai, China). In the planned CIPHER trial, the CIRT will be administered to US patients at the National Institute of Radiological Sciences or the Italian National Center of Oncological Hadron Therapy (Pavia, Italy). The CIPHER trial is designed to detect an increase in 2-year OS from 22% with IMRT to 48% with carbon ions. 8 
CONCLUSIONS
Our international colleagues should be congratulated for moving the investigations involving CIRT much further along than we or any other investigators in the United States. Through their hard work and dedication, at least 11 centers have been built to date. We must now join and support their efforts by facilitating patient accrual to phase III randomized treatment trials. The available data make it clear that we are far from making this potentially very powerful treatment modality available for the everyday care of patients with cancer. However, we are very optimistic that, by leveraging the existing expertise and existing facilities and planning the work described above, critical trials could be launched in the immediate future.
We propose designing proof-of-principle international trials to optimize treatment of the most common cancer sites (RESIDUE issues 5 and 7) through collaboration between several national and international investigators. We favor launching a series of trials that can leverage existing technology to promote and extend investigations seeking to improve CIRT survival and local control of selected cancers, ranging from rare to common. We also support the call for a registry by the Particle Therapy Cooperative Group (available at: https://ptcog.ch/index.php/clinical-protocols. Accessed July 16, 2017) to facilitate definitive comparisons. However, we believe a more aggressive but cost-conscious strategy, to include deliberate approvals for international medical regulations and standards, is greatly needed at this time. This is already underway, in that US patients with cancer are seeking CIRT in Japan, Germany, China and Italy.
For patients from the United States, we would require insurance coverage (including Medicare, which would literally require an Act of Congress) to participate in a very cost-effective set of trials. Such trials should involve patients from the United States to be sent to other countries, such as Germany or Japan, with existing CIRT facilities. Exceptions could be made to existing federal laws to allow Medicare and other insurance companies to share an appropriate portion of the cost, with differences made up by Federal research support. This potentially
Cancer December 1, 2018 would allow us to save billions of dollars in expensive investments. Concurrent with these international trials, we would recommend supporting basic research and accelerator technology advancements to be carried out in national laboratories or other national centers for developing more compact, more accurate, and less expensive CIRT technology (better machines).
Before we build additional new CIRT facilities using existing technology (which could become obsolete as ongoing technologies in this field continue to advance), we recommend that CIRT must be documented with unbiased, high level-I evidence of increased survival and quality-of-life benefits. If, within the next 10 years, these trials (conducted at existing CIRT facilities) demonstrate that there are benefits, then compact and more costeffective technologies, also to be developed over the next 5 to 10 years, could be rapidly implemented in new or existing CIRT centers. These improved accelerators could be ready for widespread production at lower cost and with more refined accuracy. In addition, new radiobiologic rationales or hypotheses developed in ion-therapy research centers could lead to new clinical trials at that time.
To determine which doses and dose constraints should be used for key trials providing level I evidence, we urgently need to address the uncertainty of RBE. The existing phase I/II trials may allow us to answer issue 1 above for all critical biologic system responses (including metabolic, immune, stem cell, and tissue homeostatic responses). Fractionation schemes based on existing RBE and assumptions will be validated using robust studies of patients who previously received CIRT. In addition, following the example of our pioneering Japanese colleagues, validation studies should be conducted using a variety of fraction sizes and dose constraints, allowing the confirmation of safety and efficacy estimates.
Therefore, we call for the standardization of CIRT treatment planning across CIRT centers. That way, when patient outcomes from CIRT trials are compared, the carbon-ion dose and fraction size will be the same for patients treated across CIRT centers, and multicenter trials across CIRT centers can be designed. Thus, participation of multiple carbon-ion centers in a multicenter, phase III, randomized clinical trial would accelerate accrual, allow cross-validation of differing carbon-ion treatment beam models, and generalize the applicability of the trial results.
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